Details for Patent: 8,715,721

Title:	Controlled release hydrocodone
Abstract:	A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
Inventor(s):	Oshlack; Benjamin (New York, NY), Huang; Hua-Pin (Englewood Cliffs, NJ), Masselink; John K. (Old Tappan, NJ), Tonelli; Alfred (Congers, NY)
Assignee:	Purdue Pharma L.P. (Stamford, CT)
Filing Date:	May 23, 2013
Application Number:	13/901,069
Claims:	1. cited by applicant . Hansch C et al.,"Comprehensive Medicinal Chemistry, vol. 5 Biopharmaceutics," Rational Design, Mechanistic Study and Therapeutic Application of Chemical Compounds, Oxford, Pergamon Press, GB, vol. 5, 1990, pp. 251-278, XP008054499. cited by applicant . Ratain M J et al., "Population Pharmacodynamic Study of Amonafide: A Cancer and Leukemia Group B Study," Journal of Clinical Oncology, Grune and Stratton, New York, NY, US, vol. 13, No. 3, Mar. 1995, pp. 741-747, XP008044974 ISSN: 0732-183X. cited by applicant . Database Medline [Online] US National Library of Medicine (NLM), Bethesda, MD, US; Aug. 1994, Yasuhara H: "Ethnic factors in evaluation of drug efficacy and safety," XP002350633 Database accession No. NLM7927070. cited by applicant . Setiabidu R et al., "Dapsone N-Acetylation, Metoprolol, Alpha-Hydroxylation, and S-Mephenytoin 4-Hydroxylation Polymorphisms in an Indonesian Population: A Cocktail and Extended Phenotyping Assessment Trail," Clinical Pharmacology & Therapeutics, Mosby-Year Book, St Louis, MO, US, vol. 56, No. 2, Aug. 1994, pp. 142-153, XP008044975 ISSN: 0009-9236. cited by applicant . "Helsinki Declaration" Online Ethics Center, [Online] Apr. 5, 2005, XP002350634 Retrieved from the Internet: URL:http://onlineethics.org/reseth/helsink i.html> retrieved on Oct. 25, 2005. cited by applicant . Castensen et al., "USP Dissolution IV:Comparison of Methods," J. Pham. Sci 1978, 67(9), pp. 1303-1307. cited by applicant . Encarta World English Dictionary [North American Edition] 2006 Microsoft Incorporation "Matrix", p. 1, definition 2, http://encarta.msn.com/encnet/features/dictionary/DictionaryResults.aspx?- - refid=1861678516 retrieved on Apr. 30, 2006. cited by applicant . Wiktionary, "dispersed," p. 1, http://en.wiktionary.org/wiki/disperse retrived on Apr. 30, 2006. cited by applicant . Abraham Sunshine et al., "Analgesic Oral Efficacy of Tramadol Hydrochloride in Postoperative Pain," Clin. Pharmacol. Ther., vol. 51, Jun. 1992, pp. 740-746. cited by applicant . E.Beubler, "Medikamentose Schmerztherapie: Kriterien, Moglichkeiten, Risken," Therapiewoche Osterreich, 7,2 (1992), pp. 1-15, English translation. cited by applicant . Gourlay, et al., "Influence of a High-Fat Metal on The Absorption of Morphine From Oral Solutions," Clin. Pharmacol. Ther., vol. 46, Oct. 1989, pp. 463-468. cited by applicant . Geoffrey K. Gourlay, et al.,"The Reproducibility of Bioavailability of Oral Morphine from Solution Under Fed and Fasted Conditions," Journal of Pain and Symtoms Management, vol. 6., No. 7, Oct. 1991, pp. 431-436. cited by applicant . Robert F. Kaiko, et al., "Controlled-Release Morphine Bioavailability (MS Contin Tablets) in the Presence and Absence of Food," The Hospice Journal, vol. 6(4) 1990, pp. 17-30. cited by applicant . Yokokawa N., et al., "Relationship between plasma concentration of morphine and analgesic effectiveness," Postgrad Med J. (1991) 67 (Suppl. 2) pp. S50-S54. cited by applicant . Physicians Desk Reference 1994, 48th Edition, pp. 1821-1824. cited by applicant . D.L. Munday, et al., "Changes in Drug Release Rate 2. Effect of Temperature and Relative Humidity on Polymeric Film Coatings," 5th Cong. Int. Tech. Pharm., 1989, vol. 2, pp. 55-60. cited by applicant . A Protocol for a clinical study entitled "A Randomized, Double-Blind, Parallel-Group Study comparing the Efficacy and Safety of Kapanol.RTM. to MS Contin.RTM. in the Management of Patients with Moderate to Severe Cancer Pain" ("The Protocol"). The date of the Protocol is indicated as Feb. 10, 1992 and it bears COD No. 14556. The sponsor of the study is indicated to be Faulding Pharmaceuticals, an Australian company. cited by applicant . Certain Patients Diary Cards, Drug Disposition Records, Case Reports Forms and listing which apparently correlates patient randomization number with the treatment of dosing regimen assigned to each patient, 2003. cited by applicant . Patient consent forms, apparently for four study participants, 2003. cited by applicant . Investigator agreements between the study organizers and certain of the principal investigators, 2003. cited by applicant . Abstracts from the Twelfth Annual Congress of the Oncology Nursing Society, May 1987, in Clinical Nursing Forum Supplement vol. 14 (2), p. 112, 1987. cited by applicant . J. Lapin et al., "Cancer Pain Management with a Controlled Release Oral Morphine Preparation," Pain and Symptom Manag., vol. 4 (3), pp. 146-151,1989. cited by applicant . J. Lapin et al., "Guidelines for Use of Controlled Release Oral Morphine in Cancer Pain Management," Cancer Nursing, vol. 12 (4), pp. 202-208, (1989). cited by applicant . R.K. Kaiko, "The Pre-and Postoperative Use of Controlled-Release Morphine (MS Contin Tablets): A Review of the Published Literature," Medical Department, The Pudue Frederick Company, Royal Society of Medical Services, International Congress, Symposium Services, No. 149, pp. 147-160 (1989). cited by applicant . H.F. Stowey et al., "Effect of Premedication with Controlled-Release Oral Morphine on Postoperative Pain," Anesthesia, 1985, vol. 40, pp. 438-440. cited by applicant . MSContin--Frequency of Daily Dosing, Jan.-Nov, 1990. cited by applicant . R.K. Portenoy, et al., "A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Pharmacolinetics and Pharmacodynamics of Kapanol.RTM. Capsules Given Every 24 hours and Every 12 hours with MS Contin.RTM. Tablets Given Every 12 Hours in the Management of Patients with Moderate to Severe Chronic Pain," Memorial Hospital IRB Protocol pp. 379-381, 1993. cited by applicant . 7th World Congress on Pain, Abstracts 997-1001, Aug. 26, 1993. cited by applicant . Advertisement: Raxanol SR., 1988 Roxane Labs, Inc. cited by applicant . T. Hunt and R. Kaiko, "Comparison of the Pharmacokinetic Profiles of Two Oral Controlled-Release Morphine Formulation in Healthy Young Adults," Clin. Thera., vol. 13, No. 4, pp. 482-488, 1991. cited by applicant . S. Bloomfield, et al., "Analgesic Efficacy and Potency of Two Oral Controlled-Release Morphine Preparations Clin. Pharmacol," Ther., vol. 53, No. 4, pp. 469-478, 1993. cited by applicant . Advertisement: MS Contin 1986, 1987 The Purdue Frederick Company. cited by applicant . Sustained Release Medications, Noyes Data Corp., pp. 3,4, 10-15, 96-99, 335-337 (1980). cited by applicant . Flanders, P., et al., "The Control of Drug Release From Conventional Melt Granulation Matrices," Drug Development and Industrial Pharmacy, vol. 13, No. 6, pp. 1001-1022 (1987). cited by applicant . McTaggart, Celia M., et al., "The evaluation of formulation and processing conditions of a melt granulation process," International Journal of Pharmaceutics, vol. 19, pp. 139-148 (1984). cited by applicant . Schaefer, T., et al., "Melt granulation in a laboratory scale high shear mixer," Drug Development and Industrial Pharmacy, vol. 16, No. 8, pp. 1249-1277 (1990). cited by applicant . Thomsen, L. Juul, et al., "Prolonged Release Matrix Pellets Prepared by Melt Pelletization I. Process Variables," Drug Development and Industrial Pharmacy, vol. 19, No. 15, pp. 1867-1887 (1993). cited by applicant . Thomsen, L. Juul, "Prolonged Release Matrix Pellets prepared by Melt Pelletization II. Hydrophobic Substances as Meltable Binders," vol. 20, No. 77, pp. 1179-1197 (1994). cited by applicant . Thomsen, L. Juul, "Utilizing melt pelletization technique for the preparation of prolonged release products," Pelletization, (material elaborated by assistant prof. Lars Jull Thomsen, Department of Pharmaceutics, Royal Danish School of Pharmacy of the DIE course "Pelletization Technology," Nov. 1992, 106 pages plus 3 appendices. cited by applicant . Thomsen, L. Juul, "Prolonged Release Matrix Pellets Prepared by Melt Pelletization. Part IV: Drug Particles Size, and Binder Composition," Pharmaceutical Technology Europa, pp. 19-24 (Oct. 1994). cited by applicant . Maccarrone C. et al.," Single Dose Pharmacokinetics of Kapanol.TM. a New Oral Sustained-Release Morphine Formulation,"Clinical Drug Investigation 1994:7 (5) 262-274. cited by applicant . West R. J., et al., "Single dose pharmacokinetics of a new oral sustained release morphine formulation, Kapanol.TM. capsules," (Abstract 997) International Association for the Study of Pain, 7th World Congress on Pain. Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant . Gourlay GK, et al., "A comparison of Kapanol.TM. (A new sustained release morphine formulation), MST Contius.RTM. and morphine solution in cancer patients: pharmacokinetics aspects," (Abstract 998) International Association for the Study of Pain, 7th World Congress on Pain Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant . Cherry DA, et al., "A comparison of Kapanol.TM. (a new sustained release morphine formulation), MST Continus.TM. and morphine solution in cancer patients: Morphine metabolite profiles and renal function," (Abstract 999) International Association for the Study of Pain, 7th World Congress on Pain, Paris Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant . Plummer JL, et al., "A comparison of Kapanol.TM. (a new sustained release morphine formulation) MST Continus.TM. and mophine solution in cancer patients: pharmcodynamic aspects," (Abstract 1000) International Association for the Study of Pain, 7th World Congress on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant . Toner G, Cramond T, Bishop, et al., "Randomized double blind, phase III crossover study of a new sustained-release oral mophine fornulation, Kapanol.TM. capsules," (Abstract 1001) International Association for the Study on Pain, Paris, Aug. 22-27, 1993 (Data on file, Glaxo Australia, F.H. Faulding). cited by applicant . Cherry DA, et al., "Once a Day (i.e. 24 Hourly) Kapanol.TM., A New Sustained Release Morphine Formulation, in the Treatment of Cancer Pain: Morphine Metabolite Profiles," European Journal of Cancer; Part A General Topics 1995; 31 (S5) Suppl:S184 Abs 884, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995. cited by applicant . Gourlay, et al., "Once a Day (i.e. 24 Hourly) Kapanol.TM., A New Sustained Release Morphine Formulation, In the Treatment of Cancer Pain: Pharmacokinetic Aspects," European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S187 Abs 897, European Conference on Clinical Oncology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995. cited by applicant . Broomhead, et al., "Kadian.TM./Kapanol.TM.--A Once Daily Mophine Formulation," European Journal of Cancer; Part A General Topics 1995:31 (S5) Suppl: S182 Abs 873, European Conference on Clinical Onclology and Cancer Nursing, Paris, Oct. 29-Nov. 2, 1995. cited by applicant . Gourlay et al., "Proceedings of the 7th World Congress on Pain; A comparison of Kapanol (a New Sustained-Release Morphine Formulation), MST Continus, and Morphine Solution in Cancer Patients," Pharmacolinetic Aspects of Morphine and Morphine Metabolites Progress in Pain Research and Management vol. 2 pp. 631-643, 1993. cited by applicant . MS Contin--Frequency of Daily Dosing (NDTI)--Jun. 1991-May 1992. cited by applicant . Kaiko R.F., "Clinical Protocol and Role of Controlled Release Morphine in the Surgical Patient," Anesthesiology and Pain Management 1991 pp. 193-212. cited by applicant . Kaiko et al., "A Single-Dose Study of the Effect of Food Ingestion and Timing of Dose Administration on the Pharmacokinetic Profile of 30-mg Sustained-Release Morphine Sulfate Tablets," Current Terapeutic Research, vol. 47, No. 5, May 1990, pp. 869-878. cited by applicant . European Search Report issued in connection with European Application No. 10177508.8-2123 on Sep. 11, 2010. cited by applicant . "The Merck Manual," Merck and Co., p. 4711 (1989). cited by applicant . Encyclopedia of Controlled Drug Delivery, vol. 1, "In vitro-in vivo correlation," pp. 425-435 (1999). cited by applicant . Encyclopedia of Controlled Drug Delivery, vol. 2, "Oral drug delivery, small intestine & colon," pp. 698-728 (1999). cited by applicant . Guidance for Industry, "Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/ In vivo Correlation" ( FDA, 1997). cited by applicant . Opinion Expressed by the Board of Appeal in the Summons to Oral Proceedings in Case EP02026247 ( May 24, 2011). cited by applicant . Goodman and Gilman's, The Pharmacological Basis of Therapeutics, pp. 7-8 (1990). cited by applicant . Office Action issued on May 24, 2011, in connection with European Application No. 10 179 087.1-2123 cited by applicant . Office Action issued on Jul. 27, 2012, in connection with European Application No. 01 992 565.0-2123. cited by applicant . Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 177 508.8-2123. cited by applicant . Office Action issued on Jul. 27, 2012, in connection with European Application No. 10 179 086.3-2123. cited by applicant . Zohydro ER Package Insert revised Oct. 2013. cited by applicant . Advisory Committee Briefing Document, NDA 20-2880, Zohydro.TM. ER Hydrocodone Bitartrate Extended-Release Capsules, Anesthetic and Analgesic Drug Products Advisory Committee, Dec. 7, 2012. cited by applicant . FDA Response to a Citizen Petition, Docket No. FDA-2013-P-0703, Oct. 25, 2013. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10180984.6. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10181032.3. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10177508.8. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 01992565.0. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179087.1. cited by applicant . Summons to attend oral proceedings issued on Jun. 5, 2013, in connection with European Patent Application No. 10179086.3. cited by applicant . Claims pending in U.S. Appl. No. 13/833,263 on Nov. 19, 2013. cited by applicant . Claims pending in U.S. Appl. No. 14/094,968 on Dec. 9, 2013. cited by applicant . Claims pending in U.S. Appl. No. 13/833,263 on Dec. 9, 2013. cited by applicant.

Primary Examiner: Sasan; Aradhana
Attorney, Agent or Firm: Davidson, Davidson & Kappel, LLC